The content on this site is intended for healthcare professionals only
Prof Helleday talks to ecancer at the IMProving care And Knowledge through Translational research (IMPAKT) meeting in Brussels, May 2012, about novel therapies for triple negative breast cancer including the use of 6-mercaptopurine, previously not used in this group of patients.
The plan is to tackle cells which have been resistant to cisplatin or PARP inhibitors; Prof Helleday discusses studies underway.
Filming Supported by Amgen
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
ESMO 2024: Highlights and analysis
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Management of HER2 positive metastatic breast cancer treatment algorithm
Post neoadjuvant management in BRCA mutant breast cancer patients
